Journal
THERANOSTICS
Volume 5, Issue 12, Pages 1456-1472Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.11692
Keywords
Breast cancer; RNA interference; Cancer stem cell; Aptamer; Survivin
Categories
Funding
- Deakin University
- Indo-Australia Science and Technology Fund [ST040007]
- Victorian Cancer Agency Platform Technology Capacity Building Grant [PTCP-02]
- CASS Foundation (Australia)
Ask authors/readers for more resources
Understanding the molecular basis of drug resistance and utilising this information to overcome chemoresistance remains a key challenge in oncology. Here we report that survivin, a key protein implicated in drug resistance, is overexpressed in cancer stem cell pool of doxorubicin-resistant breast cancer cells. Moreover, by utilising an active targeting system consisting of an RNA aptamer targeted against the epithelial cell adhesion molecule and a Dicer substrate survivin siRNA, we could deliver a high dose of the siRNA to cancer stem cells in xenograft tumours. Importantly, silencing of survivin with this aptamer-siRNA chimera in cancer stem cell population led to the reversal of chemoresistance, such that combined treatment with low dose of doxorubicin inhibited stemness, eliminated cancer stem cells via apoptosis, suppressed tumour growth, and prolonged survival in mice bearing chemoresistant tumours. This strategy for in vivo cancer stem cell targeting has wide application for future effective silencing of anti-death genes and in fact any dysregulated genes involved in chemoresistance and tumour relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available